X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs J.B.CHEMICALS - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH J.B.CHEMICALS PANACEA BIOTECH/
J.B.CHEMICALS
 
P/E (TTM) x -6.4 17.1 - View Chart
P/BV x 1.9 2.3 81.9% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 PANACEA BIOTECH   J.B.CHEMICALS
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
J.B.CHEMICALS
Mar-16
PANACEA BIOTECH/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs149318 46.7%   
Low Rs82200 41.3%   
Sales per share (Unadj.) Rs84.1148.0 56.9%  
Earnings per share (Unadj.) Rs-18.319.1 -95.9%  
Cash flow per share (Unadj.) Rs-6.723.9 -28.0%  
Dividends per share (Unadj.) Rs00.50 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs83.7128.9 64.9%  
Shares outstanding (eoy) m61.2584.82 72.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.41.7 78.5%   
Avg P/E ratio x-6.313.6 -46.5%  
P/CF ratio (eoy) x-17.210.8 -159.5%  
Price / Book Value ratio x1.42.0 68.7%  
Dividend payout %02.6 0.0%   
Avg Mkt Cap Rs m7,07421,951 32.2%   
No. of employees `0002.82.7 100.6%   
Total wages/salary Rs m1,4491,841 78.7%   
Avg. sales/employee Rs Th1,874.14,590.9 40.8%   
Avg. wages/employee Rs Th527.0673.4 78.3%   
Avg. net profit/employee Rs Th-407.7592.1 -68.9%   
INCOME DATA
Net Sales Rs m5,15412,551 41.1%  
Other income Rs m100542 18.4%   
Total revenues Rs m5,25413,093 40.1%   
Gross profit Rs m-7662,055 -37.3%  
Depreciation Rs m711412 172.4%   
Interest Rs m1,50396 1,570.5%   
Profit before tax Rs m-2,8812,088 -137.9%   
Minority Interest Rs m110 -2,700.0%   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17469 3.6%   
Profit after tax Rs m-1,1211,619 -69.3%  
Gross profit margin %-14.916.4 -90.8%  
Effective tax rate %-0.622.5 -2.6%   
Net profit margin %-21.812.9 -168.7%  
BALANCE SHEET DATA
Current assets Rs m3,8107,778 49.0%   
Current liabilities Rs m8,3654,358 192.0%   
Net working cap to sales %-88.427.2 -324.4%  
Current ratio x0.51.8 25.5%  
Inventory Days Days15655 284.8%  
Debtors Days Days6780 84.0%  
Net fixed assets Rs m14,4805,713 253.5%   
Share capital Rs m61170 36.1%   
"Free" reserves Rs m90310,547 8.6%   
Net worth Rs m5,12710,937 46.9%   
Long term debt Rs m5,8320-   
Total assets Rs m19,43315,574 124.8%  
Interest coverage x-0.922.8 -4.0%   
Debt to equity ratio x1.10-  
Sales to assets ratio x0.30.8 32.9%   
Return on assets %2.011.0 17.8%  
Return on equity %-21.914.8 -147.8%  
Return on capital %3.620.0 18.2%  
Exports to sales %24.548.7 50.3%   
Imports to sales %10.27.1 143.8%   
Exports (fob) Rs m1,2646,115 20.7%   
Imports (cif) Rs m525889 59.1%   
Fx inflow Rs m1,5396,169 25.0%   
Fx outflow Rs m9421,285 73.3%   
Net fx Rs m5974,884 12.2%   
CASH FLOW
From Operations Rs m5991,397 42.9%  
From Investments Rs m-438-320 136.7%  
From Financial Activity Rs m-303-1,196 25.3%  
Net Cashflow Rs m-141-102 138.1%  

Share Holding

Indian Promoters % 74.5 55.4 134.5%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 0.6 3.4 17.7%  
FIIs % 1.3 3.9 33.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 37.0 63.8%  
Shareholders   10,259 30,437 33.7%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  NOVARTIS  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Dec 14, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - DR. DATSONS LABS COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS